We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+16.16%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
+$59.8M
Cap. Flow
+$91.1M
Cap. Flow %
8.85%
Top 10 Hldgs %
91.97%
Holding
24
New
3
Increased
2
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
SGP
SpyGlass Pharma
SGP
+$56.8M
2
STRO icon
Sutro Biopharma
STRO
+$15.5M
3
ALMS
Alumis Inc
ALMS
+$14.7M
4
AGMB
AgomAb Therapeutics NV
AGMB
+$8.5M
5
CHRS icon
Coherus Oncology
CHRS
+$6.09M

Top Sells

Rank Stock Value
1
PVLA
Palvella Therapeutics
PVLA
+$6.92M
2
ABVX
Abivax
ABVX
+$2.23M
3
CTNM
Contineum Therapeutics
CTNM
+$826K
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$477K
5
NUVB.WS
Nuvation Bio Inc Warrants
NUVB.WS
+$41K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$6.33B
$339M 32.95%
6,897,652
– –
MLYS icon
2
Mineralys Therapeutics
MLYS
$2.39B
$159M 15.45%
5,871,018
– –
ALMS
3
Alumis Inc
ALMS
$3.65B
$140M 13.58%
6,345,219
+588,235
+10% +$14.7M
SEPN
4
Septerna Inc
SEPN
$1.51B
$75.7M 7.35%
3,149,128
– –
KLRS
5
Kalaris Therapeutics
KLRS
$104M
$74.7M 7.26%
12,948,081
– –
SGP
6
SpyGlass Pharma
SGP
$661M
$54.7M 5.31%
+2,109,953
New +$56.8M
NGNE icon
7
Neurogene
NGNE
$744M
$34.6M 3.36%
1,717,127
– –
IVA
8
Inventiva
IVA
$1.09B
$28.8M 2.8%
5,194,805
– –
STRO icon
9
Sutro Biopharma
STRO
$391M
$26.5M 2.57%
1,062,872
+858,369
+420% +$15.5M
JBIO
10
Jade Biosciences
JBIO
$1.27B
$13.6M 1.32%
968,798
– –
VTVT icon
11
vTv Therapeutics
VTVT
$130M
$11.8M 1.15%
298,496
– –
AQST icon
12
Aquestive Therapeutics
AQST
$517M
$10.4M 1.01%
2,500,000
– –
XFOR icon
13
X4 Pharmaceuticals
XFOR
$360M
$7.57M 0.74%
1,832,566
-127,434
-7% -$477K
NKTX icon
14
Nkarta
NKTX
$186M
$7.4M 0.72%
3,507,666
– –
ACLX
15
DELISTED
Arcellx
ACLX
$6.99M 0.68%
60,873
– –
UPB
16
Upstream Bio Inc
UPB
$381M
$6.62M 0.64%
736,047
– –
ABVX
17
Abivax
ABVX
$11.9B
$6.3M 0.61%
56,581
-18,861
-25% -$2.23M
AGMB
18
AgomAb Therapeutics NV
AGMB
$593M
$6.29M 0.61%
+600,000
New +$8.5M
RANI icon
19
Rani Therapeutics
RANI
$78.4M
$6.25M 0.61%
8,500,000
– –
CHRS icon
20
Coherus Oncology
CHRS
$216M
$5.79M 0.56%
+3,428,571
New +$6.09M
PVLA
21
Palvella Therapeutics
PVLA
$2.26B
$4.79M 0.47%
38,432
-66,385
-63% -$6.92M
GOSS icon
22
Gossamer Bio
GOSS
$83.2M
$2.37M 0.23%
7,222,559
– –
NUVB.WS
23
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
– –
-124,119
Closed -$41K
CTNM
24
Contineum Therapeutics
CTNM
$532M
– –
-72,245
Closed -$826K

Similar funds

OTL
Oak Thistle LLC New York $1.03B AUM 20.63% 1-Year Est. Return
TCM
Tributary Capital Management Omaha, Nebraska $1.03B AUM 19.64% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
TWM
Tanager Wealth Management Goring On Thames, United Kingdom $1.03B AUM 16.43% 1-Year Est. Return

Samsara BioCapital's Q1 2026 Portfolio in Review

As of Q1 2026, Samsara BioCapital held 24 positions worth $1.03B, up 6.2% from $969M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Samsara BioCapital deployed $91.1M of net new capital in Q1 2026, opening 3 new positions and adding to 2 existing holdings. Its largest new stake was SpyGlass Pharma: 2,109,953 shares worth $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Palvella Therapeutics, an estimated $6.92M trimmed.

  • Samsara BioCapital's largest Q1 2026 buy was SpyGlass Pharma: 2,109,953 shares worth $54.7M.
  • Samsara BioCapital added most to Sutro Biopharma in Q1 2026, an estimated $15.5M increase.
  • Samsara BioCapital's biggest Q1 2026 reduction was Palvella Therapeutics, cutting an estimated $6.92M.
  • Samsara BioCapital fully exited Contineum Therapeutics in Q1 2026, selling an estimated $826K.
  • Samsara BioCapital's ten largest holdings make up 92% of its $1.03B portfolio in Q1 2026.
  • Samsara BioCapital opened 3 new positions and closed 2 in Q1 2026.
  • Samsara BioCapital's portfolio value rose 6.2% quarter-over-quarter to $1.03B.

Based on Samsara BioCapital's 13F filing for Q1 2026, filed 15 May 2026.